Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71205-398

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71205-398). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (269f0768 2e6c 4188 Ba86 2d7420d31a21 01)

FDA Label Image

Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4 (269f0768 2e6c 4188 Ba86 2d7420d31a21 02)

This is a graph showing the estimated probability of response for Rizatriptan Benzoate Tablets with two different strengths (10mg and 5mg) over time (0 to 2 hours post-dose). The response probability ranges from 80% to 100% with the highest probability at 1 hour post-dose.*

FDA Label Image

Estimated Probablity Of Remedication Or Response Vs. Hrs Post-dose For Rizatriptan Tablets (269f0768 2e6c 4188 Ba86 2d7420d31a21 03)

This text does not provide a useful description. It seems to be a table or chart showing the estimated probability of remedication or rescue at different time intervals after taking different types of tablets, specifically Ristriptan Bensoste Tablets and Rizatriptan Benzoate Tablets. Without additional context and information, it is not possible to generate a meaningful description.*

FDA Label Image

Estimated Probablity Of Response Vs. Hrs Post-dose For Rizatriptan Odt (269f0768 2e6c 4188 Ba86 2d7420d31a21 04)

This is a description of a medication called Rizatriptan Benzoate Orally Disintegrating Tablets USP, available in 5mg and 10mg doses. There is also a graph showing the percentage of effectiveness over time after taking the medication.*

FDA Label Image

Estimated Probablity Of Remedication Of Rescue Vs. Hrs Post-dose For Rizatriptan Odt (269f0768 2e6c 4188 Ba86 2d7420d31a21 05)

This appears to be a graph showing estimated probability of remedication or rescue for two types of Rizatrptan Benzoste Orally Disintegrating Tablets, with varying percentages ranging from 0% to 100%, over a 14-hour period post-dose. The accuracy of the text is uncertain due to the presence of errors.*

FDA Label Image

Observed Percentage Versus Hours Post Stage 2 Dose (269f0768 2e6c 4188 Ba86 2d7420d31a21 06)

This text represents a graph or chart showing the percentage concentration of Rizatriptan Benzoate orally disintegrating tablets compared to a placebo over a period of time, as measured by hours post the second dose (which presumably was given during Stage 2 of a clinical trial). There is not enough information to interpret the graph further.*

FDA Label Image

Company Logo (269f0768 2e6c 4188 Ba86 2d7420d31a21 07)

This is a company named Unichem Pharmaceuticals (USA), Inc.*

FDA Label Image

Company Logo (269f0768 2e6c 4188 Ba86 2d7420d31a21 08)

This text only includes the name of a company: "UNICHEM PHARMACEUTICALS (USA). INC." It does not provide any context or useful description.*

FDA Label Image

71205-398-06 (269f0768 2e6c 4188 Ba86 2d7420d31a21 10)

This is a product description for a medication called Rizatriptan Benzoate. The medication comes in orally disintegrating tablets and is used to treat migraines. The tablets are white or off-white, round, flat faced, and bevelled edge. The product is manufactured by Unichem Laboratories Ltd in India and comes in a 1x6 package with a lot number and expiration date. The medication should be stored at 20°-25°C and kept out of the reach of children. The product code is SR039806 and the GTIN is 0371205398064.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.